- Home
- STRO vs ACIU Comparison
STRO vs ACIU Comparison
Compare STRO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- ACIU
- Stock Information
- Founded
- STRO 2003
- ACIU 2003
- Country
- STRO United States
- ACIU Switzerland
- Employees
- STRO N/A
- ACIU N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- ACIU Health Care
- Exchange
- STRO Nasdaq
- ACIU Nasdaq
- Market Cap
- STRO 183.9M
- ACIU 332.4M
- IPO Year
- STRO 2018
- ACIU 2016
- Fundamental
- Price
- STRO $2.12
- ACIU $2.95
- Analyst Decision
- STRO Strong Buy
- ACIU Strong Buy
- Analyst Count
- STRO 7
- ACIU 2
- Target Price
- STRO $12.14
- ACIU $12.00
- AVG Volume (30 Days)
- STRO 1.3M
- ACIU 118.7K
- Earning Date
- STRO 11-13-2024
- ACIU 11-05-2024
- Dividend Yield
- STRO N/A
- ACIU N/A
- EPS Growth
- STRO N/A
- ACIU N/A
- EPS
- STRO N/A
- ACIU N/A
- Revenue
- STRO $160,955,000.00
- ACIU $48,505,404.00
- Revenue This Year
- STRO N/A
- ACIU $85.33
- Revenue Next Year
- STRO N/A
- ACIU $80.69
- P/E Ratio
- STRO N/A
- ACIU N/A
- Revenue Growth
- STRO 230.90
- ACIU 4097200.00
- 52 Week Low
- STRO $2.08
- ACIU $2.25
- 52 Week High
- STRO $6.13
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- STRO 28.49
- ACIU 36.56
- Support Level
- STRO $2.66
- ACIU $3.10
- Resistance Level
- STRO $3.01
- ACIU $3.21
- Average True Range (ATR)
- STRO 0.19
- ACIU 0.11
- MACD
- STRO -0.03
- ACIU -0.04
- Stochastic Oscillator
- STRO 4.30
- ACIU 7.02
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.